InTouch Newsletter Issue 8

Congresses and Events

New EWOLUTION two-year results confirm that WATCHMAN™ is safe and effective in stroke risk reduction

The EWOLUTION 2 years data presented at EHRA 2018 congress, confirm that WATCHMAN is safe and effective in stroke risk reduction. EWOLUTION, the largest prospective real-life study on WATCHMAN, showed a high success of implant and sealing, with low procedural adverse event rates.1
Learn more

Use of the GUIDEZILLA™ II Guide Extension Catheter in Order to Deliver Stents in Tortuous and Calcified Distal Lesions



Dr. Tim G. Schäufele
Robert-Bosch-Krankenhaus Stuttgart, Germany
The percentage of complex procedures has increased significantly over the last years, bringing along the need to use the best tools to manage complications. GUIDEZILLA™ II is a new Guide Extension Catheter which provides additional back-up support and facilitates easy delivery of ancillary devices. Learn more about Dr. Schäufele’s experience in using GUIDEZILLA II through complex anatomies.
Learn more

Dr. Ferenc is using SAMURAI™ Workhorse Wire for its trackability and pushability in complex lesions

Learn more about Dr M. Ferenc’s experience in using SAMURAI Workhorse Wires, which are part of the SENTAI family, a high-performance line of Japanese-enginereed guidewires.
SAMURAI’s innovative design provides exceptional torque performance, trackability and pushability in tortuous anatomy. 
Learn more

References

1. Boersma LV et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year followup outcome data of the EWOLUTION trial. Heart Rhythm. 2017 Sep;14(9):1302-1308.

Educational Corner

Left main bifurcation in elderly patient at high risk of bleeding

A case imaging presented by Dr. S. Watkins, who illustrates how to do a culotte bifurcation technique with a step by step approach, presenting unique bench views of the stent deployment. The use of IVUS and the choice of the stent to use can help achieve successful outcomes in the treatment of Left Main bifurcations in complex high risk patient (CHIP).

Learn more

IncathLab Live Case: New fundamentals and perspectives in coronary stenting

A panel of experts show how to master complex lesions and manage complications, by comparing different techniques and discussing the choice of devices.  Watch this web symposium to improve your knowledge on coronary angioplasty and learn more about the best approach strategies you can adopt.
Learn more

Treat complex lesions with the new WOLVERINE™ Cutting Balloon

Coronary cutting balloon is intended for opening coronary arteries in those circumstances where a resistant lesion is encountered and unable to be opened with traditional balloon angioplasty.  

The new WOLVERINE™ Cutting Balloon combines a proprietary atherotome and low pressure balloon design to directly address complex lesions and complications.

Learn more

Clinical Studies

ACURATE neo™ Aortic Valve System shows safety & efficacy results comparable to SAPIEN 3¹

Multi-centre comparison study1 between ACURATE neo Aortic Valve System and Edwards SAPIEN 3 Transcatheter Heart Valve (JACC Cardiovascular Interventions) shows comparable procedural outcomes.

  • Comparable procedural outcomes
  • Superior hemodynamics
  • Lower new permanent pacemaker implantation rates
See Won-Keun Kim’s interview from PCR London Valves 2017 and read the publication to learn more.
Learn more

SYNTAX™ II Study: CABG-like outcomes with SYNERGY™ BP Stent in patients with multi-vessel disease

Physiological assessment, use of the SYNERGY™ BP-EES Stent, IVUS guidance and complete revascularization of CTOs using contemporary CTO techniques, leads to CABG-like outcomes in patients with three-vessel disease. This is the result of the SYNTAX™ II Study, which evaluated the SYNERGY™ BP-EES Stent in a procedure-related trial involving a multitude of variables when treating patients with three-vessel disease.
Learn more

ACURATE neo™: A “very safe” TAVI system providing “extremely good results in almost all patients”

In February’s issue of Cardiovascular News, Dr. C. Hengstenberg comments that with the ACURATE neo valve, “you have very high rates of implantation success and a low pacemaker rate”.
Read the article to learn more about his experience and see Prof. Dr. med. H. Möllmann presenting the ACURATE neo device as well as SAVI TF 1000 patients registry.
Learn more
References
1. Husser O, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2078-2087
** According to VARC-2, elevated gradients >20 mmHg are defined as mild stenosis, are assessed as Device Failure and may indicate prosthetic valve dysfunction.

Further Information

Download PDF
Previous Issues
Top